Baseline characteristics of early DMARD-naive patients with RA participating in the SWEFOT trial
| SWEFOT* (n=403) | Univariate† (n=215) | Multivariate‡ (n=154) | |
| Proportions, n (%) | |||
| Obese (BMI ≥30 kg/m2) | 43 (17) | 39 (18) | 26 (17) |
| Overweight (BMI=25–29.9) | 74 (28) | 62 (29) | 39 (25) |
| Normal (BMI <25) | 143 (55) | 114 (53) | 89 (58) |
| Female sex | 285 (71) | 152 (71) | 111 (72) |
| Current smokers | 41 (23) | 34 (22) | 34 (22) |
| RF positive | 274 (69) | 141 (66) | 95 (62) |
| ACPA positive | 237 (63) | 127 (64) | 92 (63) |
| Concurrent prednisolone | 58 (14) | 28 (13) | 19 (13) |
| Medians (IQR) | |||
| Age, years | 56 (45–64) | 56 (44–63) | 56 (44–63) |
| Symptom duration, months | 5 (4–8) | 6 (4–8) | 6 (4–9) |
| DAS28 | 5.7 (4.9–6.3) | 5.9 (5.1–6.5) | 5.9 (5.2–6.6) |
| HAQ score | 1.1 (0.8–1.5) | 1.3 (0.9–1.8) | 1.2 (0.8–1.8) |
↵Patients with available BMI for univariate analyses or with all data available for the multivariate model did not differ from the original SWEFOT trial population.
Proportions, n (%), were compared with Pearson’s χ2 , Continuous variables, medians (IQR), were compared with independent samples Mann-Whitney U tests.
*All patients who originally participated in the SWEFOT. Missing data were as follows in number, n: BMI, 143; smoking status, 221; RF status, 4; anti-ACPA status, 25; concurrent prednisolone use, 3; HAQ, 6.
†Univariate model, where the DAS28 at 24 months and baseline BMI were required. Missing data (n) were as follows: smoking status, 59; RF status, 1; ACPA status, 15; concurrent prednisolone use, 3; and HAQ, 4.
↵‡Multivariate model shown in table 2 and figure 3A. Missing data points (n) were as follows: RF status, 1; ACPA status, 7; concurrent prednisolone use, 2.
ACPA, anticitrullinated protein antibody; BMI, body mass index; DAS28, 28-joint count Disease Activity Score; DMARD, disease-modifying rheumatic drug; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RF, rheumatoid factor; SWEFOT, Swedish Pharmacotherapy Trial.